Long-Term Maintenance of Clinical Responses by Individual Patients With Polyarticular-Course Juvenile Idiopathic Arthritis Treated With Abatacept.

Fecha de publicación: 23/05/2023 Fecha Ahead of Print: 23/05/2023

Autores de IIS La Fe

• 

  Inmaculada Calvo Penadés

  Autor

Participantes ajenos a IIS La Fe

• Brunner, Hermine I
• Tzaribachev, Nikolay
• Louw, Ingrid
• Avila-Zapata, Francisco
• Horneff, Gerd
• Foeldvari, Ivan
• Kingsbury, Daniel J
• Gastanaga, Maria Eliana Paz
• Wouters, Carine
• Breedt, Johannes
• Wong, Robert
• Askelson, Margarita
• Zhuo, Joe
• Martini, Alberto
• Lovell, Daniel J
• Ruperto, Nicolino
• Paediatric Rheumatology International Trials Organisation (PRINTO) and
• the Pediatric Rheumatology Collaborative Study Group (PRCSG)
• investigators

Grupos

• Reumatología Pediátrica

  

  Investigador establecido

  Inmaculada Calvo Penadés

Abstract

OBJECTIVE: To investigate the frequency and trajectories of individual patients with polyarticular-course juvenile idiopathic arthritis (pJIA) achieving novel composite endpoints on abatacept. METHODS: Data from a clinical trial of subcutaneous abatacept (NCT01844518) and a post hoc analysis of intravenous abatacept (NCT00095173) in patients with pJIA were included. Three endpoints were defined and evaluated; combined occurrence of low disease activity (LDA) measured by the Juvenile Arthritis Disease Activity Score, 50% improvement in JIA-American College of Rheumatology criteria (ACR50), and patient-reported outcomes (PRO). PROs included visual analog scale (VAS) of minimal pain (pain-min) and Childhood Health Assessment Questionnaire-disability index score of 0 (CHAQ-DI0). In this post hoc analysis, maintenance of month 13 and 21 endpoints (LDA+pain-min, LDA+CHAQ-DI0, and ACR50+pain-min) in those who achieved them at month 4 was determined. RESULTS: Composite endpoints (LDA+pain-min, LDA+CHAQ-DI0, and ACR50+pain-min) were achieved at month 4: 44.7%, 19.6%, and 58.9% of the 219 patients treated with SC abatacept, respectively. Of those who achieved LDA+pain-min at month 4, 84.7% (83/98) and 65.3% (64/98) maintained LDA+pain-min at months 13 and 21, respectively. The proportions of patients meeting LDA+pain-min outcomes increased from 44.7% (98/219) at month 4 to 54.8% (120/219) at month 21. The frequency of patients who met LDA+CHAQ-DI0 increased from 19.6% (43/219) at month 4 to 28.8% (63/219) at month 21. CONCLUSIONS: Among individual patients with pJIA treated with abatacept who achieved one of the combined clinical and PRO composite endpoints, many maintained them over 21 months of abatacept treatment.

This article is protected by copyright. All rights reserved.

Keywords

• DISEASE-ACTIVITY SCORE; CHILDREN; PAIN